Fig. 4

UBE2L3 is the target gene of miR-744-5p. a Three common mRNAs were screened out in microT, TargetScan, miRmap databases via ENCORI. b qRT-PCR was executed to quantify expression of the three mRNAs when miR-744-5p was overexpressed in cells. c qRT-PCR quantified the expression of UBE2L3 in prostate cancer cells and RWPE-1. d qRT-PCR tested the expression of UBE2L3 when the expression of LINC01116 was silenced in cells. e, f RIP and RNA pull down assays were utilized to prove the interaction of LINC01116, miR-744-5p and UBE2L3. g The alignment between UBE2L3 and miR-744-5p were predicted by ENCORI. h The luciferase activity of UBE2L3-WT was detected through luciferase reporter assay with miR-744-5p overexpression. i qRT-PCR detected the effectiveness of miR-744-5p inhibitor. j qRT-PCR was executed to quantify the expression of UBE2L3 when sh-LINC01116#1 or sh-LINC01116#1 + miR-744-5p inhibitor was transfected into cells. *P < 0.05, **P < 0.01